aTyr Pharma Awaits FDA Response on Phase 3 Sarcoidosis Study Protocol

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-02
Category: health
Source: Pharma Now

aTyr Pharma is anticipating a response from the FDA by mid-September 2026 regarding its Phase 3 protocol for efzofitimod, a treatment under investigation for pulmonary sarcoidosis.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai